The supplementation of L-carnitine in septic shock patients: Systematic review and meta-analysis

Bibliographic Details
Main Author: Guedes, Gabriel Voltani
Publication Date: 2022
Other Authors: Minicucci, Marcos Ferreira, Tanni, Suzana Erico
Format: Article
Language: eng
Source: Clinics
Download full: https://www.revistas.usp.br/clinics/article/view/213582
Summary: Background: Sepsis and septic shock are severe and difficult-to-treat conditions with high lethality. There is interest in identifying new adjunct therapies that are effective in reducing mortality. In this context, L-carnitine has been investigated in trials as a potentially beneficial drug. Therefore, the aim of this systematic review was to assess the clinical evidence to support the use of L-carnitine in septic shock patients to reduce the risk of mortality. The objective of this review was to evaluate the effect of L-carnitine compared to placebo or Usual Care (UC) on the mortality rate in hospitalized adult septic shock patients. Methods: The authors exclusively included randomized clinical trials that compared the use of L-carnitine versus placebo in adult (> 18 years old) septic shock patients. The outcome was a mortality rate of 28 days. This systematic review and meta-analysis were performed following the PRISMA guidelines and registered in PROSPERO with the ID CRD42020180499. Results: Following the initial search, 4007 citations were identified, with 2701 remaining after duplicate removal. Eight citations were selected for body text reading, and two were selected for inclusion. The studies enrolled 275 patients, with 186 in the carnitine arm and 89 in the placebo arm. The effect of L-carnitine uses in septic shock patients showed a difference risk of -0.03 (95% Confidence Interval: -0.15–0.10, I2 = 77%, p = 0.69) compared to placebo/in mortality rate with low quality of evidence. Conclusions: There is low-quality evidence that the use of L-carnitine has no significant effect on reducing 28-day mortality in septic shock patients.
id USP-19_d7d00a5f917bea92351b92fb7fdd08e0
oai_identifier_str oai:revistas.usp.br:article/213582
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling The supplementation of L-carnitine in septic shock patients: Systematic review and meta-analysisL-carnitineSeptic shockMortalityMitochondrial dysfunctionBackground: Sepsis and septic shock are severe and difficult-to-treat conditions with high lethality. There is interest in identifying new adjunct therapies that are effective in reducing mortality. In this context, L-carnitine has been investigated in trials as a potentially beneficial drug. Therefore, the aim of this systematic review was to assess the clinical evidence to support the use of L-carnitine in septic shock patients to reduce the risk of mortality. The objective of this review was to evaluate the effect of L-carnitine compared to placebo or Usual Care (UC) on the mortality rate in hospitalized adult septic shock patients. Methods: The authors exclusively included randomized clinical trials that compared the use of L-carnitine versus placebo in adult (> 18 years old) septic shock patients. The outcome was a mortality rate of 28 days. This systematic review and meta-analysis were performed following the PRISMA guidelines and registered in PROSPERO with the ID CRD42020180499. Results: Following the initial search, 4007 citations were identified, with 2701 remaining after duplicate removal. Eight citations were selected for body text reading, and two were selected for inclusion. The studies enrolled 275 patients, with 186 in the carnitine arm and 89 in the placebo arm. The effect of L-carnitine uses in septic shock patients showed a difference risk of -0.03 (95% Confidence Interval: -0.15–0.10, I2 = 77%, p = 0.69) compared to placebo/in mortality rate with low quality of evidence. Conclusions: There is low-quality evidence that the use of L-carnitine has no significant effect on reducing 28-day mortality in septic shock patients.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2022-10-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/21358210.1016/j.clinsp.2022.100124Clinics; Vol. 77 (2022); 100124Clinics; v. 77 (2022); 100124Clinics; Vol. 77 (2022); 1001241980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/213582/195666Copyright (c) 2023 Clinicsinfo:eu-repo/semantics/openAccessGuedes, Gabriel VoltaniMinicucci, Marcos FerreiraTanni, Suzana Erico2023-07-06T13:04:59Zoai:revistas.usp.br:article/213582Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2023-07-06T13:04:59Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv The supplementation of L-carnitine in septic shock patients: Systematic review and meta-analysis
title The supplementation of L-carnitine in septic shock patients: Systematic review and meta-analysis
spellingShingle The supplementation of L-carnitine in septic shock patients: Systematic review and meta-analysis
Guedes, Gabriel Voltani
L-carnitine
Septic shock
Mortality
Mitochondrial dysfunction
title_short The supplementation of L-carnitine in septic shock patients: Systematic review and meta-analysis
title_full The supplementation of L-carnitine in septic shock patients: Systematic review and meta-analysis
title_fullStr The supplementation of L-carnitine in septic shock patients: Systematic review and meta-analysis
title_full_unstemmed The supplementation of L-carnitine in septic shock patients: Systematic review and meta-analysis
title_sort The supplementation of L-carnitine in septic shock patients: Systematic review and meta-analysis
author Guedes, Gabriel Voltani
author_facet Guedes, Gabriel Voltani
Minicucci, Marcos Ferreira
Tanni, Suzana Erico
author_role author
author2 Minicucci, Marcos Ferreira
Tanni, Suzana Erico
author2_role author
author
dc.contributor.author.fl_str_mv Guedes, Gabriel Voltani
Minicucci, Marcos Ferreira
Tanni, Suzana Erico
dc.subject.por.fl_str_mv L-carnitine
Septic shock
Mortality
Mitochondrial dysfunction
topic L-carnitine
Septic shock
Mortality
Mitochondrial dysfunction
description Background: Sepsis and septic shock are severe and difficult-to-treat conditions with high lethality. There is interest in identifying new adjunct therapies that are effective in reducing mortality. In this context, L-carnitine has been investigated in trials as a potentially beneficial drug. Therefore, the aim of this systematic review was to assess the clinical evidence to support the use of L-carnitine in septic shock patients to reduce the risk of mortality. The objective of this review was to evaluate the effect of L-carnitine compared to placebo or Usual Care (UC) on the mortality rate in hospitalized adult septic shock patients. Methods: The authors exclusively included randomized clinical trials that compared the use of L-carnitine versus placebo in adult (> 18 years old) septic shock patients. The outcome was a mortality rate of 28 days. This systematic review and meta-analysis were performed following the PRISMA guidelines and registered in PROSPERO with the ID CRD42020180499. Results: Following the initial search, 4007 citations were identified, with 2701 remaining after duplicate removal. Eight citations were selected for body text reading, and two were selected for inclusion. The studies enrolled 275 patients, with 186 in the carnitine arm and 89 in the placebo arm. The effect of L-carnitine uses in septic shock patients showed a difference risk of -0.03 (95% Confidence Interval: -0.15–0.10, I2 = 77%, p = 0.69) compared to placebo/in mortality rate with low quality of evidence. Conclusions: There is low-quality evidence that the use of L-carnitine has no significant effect on reducing 28-day mortality in septic shock patients.
publishDate 2022
dc.date.none.fl_str_mv 2022-10-31
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/213582
10.1016/j.clinsp.2022.100124
url https://www.revistas.usp.br/clinics/article/view/213582
identifier_str_mv 10.1016/j.clinsp.2022.100124
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/213582/195666
dc.rights.driver.fl_str_mv Copyright (c) 2023 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 77 (2022); 100124
Clinics; v. 77 (2022); 100124
Clinics; Vol. 77 (2022); 100124
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1824324359732330496